Results 191 to 200 of about 700,247 (353)

Acute kidney injury and morbi‐mortality associated with “triple whammy” combination: Systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims “Triple whammy” (TW) refers to the concomitant use of diuretics, renin‐angiotensin‐aldosterone system inhibitors (RAASI) and non‐steroidal anti‐inflammatory drugs (NSAIDs). The aim of this article is to analyse the association between TW exposure and acute kidney injury (AKI), among other morbi‐mortality outcomes.
Dulce María Calvo, Luis Carlos Saiz, Leire Leache, Maria Concepción Celaya, Marta Gutiérrez‐Valencia   +4 more
wiley   +1 more source

Pulmonary Hypertension: Let's Take Stock! [PDF]

Life (Basel)
Cacia M, Imbalzano E, Ciconte VA, Vatrano M.   +3 more
europepmc   +1 more source

PATHOGENESIS OF THE PULMONARY HYPERTENSION IN PATIENTS WITH PULMONARY EMPHYSEMA AND PULMONARY TUBERCULOSIS

, 1958
Komei Ishikawa, Kiichiro Tanemoto, Yuzuru Fujiwara, Takeshi Ando, Minoru Yoshida, Yoshihiko Ike, Osamu Matsuo   +6 more
openalex   +2 more sources

The Electrocardiogram in Children with Ventricular Septal Defect and Severe Pulmonary Hypertension [PDF]

, 1960
James W. DuShane, William H. Weidman, Robert O. Brandenburg, John W. Kirklin   +3 more
openalex   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Will Stub1 Be the Next Target for Pulmonary Hypertension Therapy Development? [PDF]

Am J Respir Cell Mol Biol
Shen Y.
europepmc   +1 more source

Embolization of pulmonary AVMs: no consistent effect on pulmonary artery pressure [PDF]

, 2008
Davies, RJ, Gibbs, JSR, Jackson, JE, Shovlin, CL, Tighe, HC   +4 more
core   +1 more source

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice

British Journal of Clinical Pharmacology, EarlyView.
Aims Adherence to disease‐modifying antirheumatic drugs (DMARDs) has been associated with improved treatment outcomes, but how adherence is reported ranges between studies. We therefore aimed to determine how nonadherence to DMARDs used to treat rheumatoid arthritis (RA) has been measured and to report the nonadherence rate with each measure identified.
Lauren Fraser, Nagham Ailabouni, Lisa Kalisch Ellett, Jiun Ming Tan, Anthea Freeman, Susanna M. Proudman, Emily Reeve, Michael D. Wiese   +7 more
wiley   +1 more source

The Surgical Management of Chronic Thromboembolic Pulmonary Hypertension. [PDF]

J Clin Med
McGann KC, Wang CC, Trahanas JM, Bommareddi S, Lima B, Ahmad A, Chin CW, Robbins IM, Pugh ME, Hemnes AR, Funke B, Shah AS, Williams AM.   +12 more
europepmc   +1 more source

Familial primary pulmonary hypertension.

, 1966
Wayne R. Parry, D. Vérel
openalex   +1 more source